10 reports

Pharmaceutical: The pharmaceutical segment includes products for areas such as anti-infective, antipsychotic, contraceptive, hematology, gastrointestinal, immunology, infectious diseases, oncology, neurology, pain management, thrombosis, and JOHNSON & JOHNSON BUSINESS OVERVIEW Source: T

  • Smoking Cessation
  • United States
  • Market Size
  • GlaxoSmithKline plc
  • Novartis AG

gastrointestinal and urinary conditions, and arthritis EVOTEC GAMUCCI JAPAN TOBACCO LOGIC TECHNOLOGY NICOTEK NOVARTIS Company REVOLYMER Description TARGET THE HARVARD DRUG GROUP Retailing company based in the US Designs, develops, and formulates polymers in the UK, Canada, Germany, Italy, a

  • Smoking Cessation
  • GlaxoSmithKline plc
  • ITC Limited
  • Pfizer Inc.
  • Reynolds American Inc.
  • SMALL MOLECULES TO ANTAGONIZE CHRNA4 AND CHRNB2 FOR NICOTINE ADDICTION - DRUG PROFILE
  • Smoking Cessation
  • Therapy
  • United States
  • World
  • Product Initiative
  • SMALL MOLECULES TO ANTAGONIZE CHRNA4 AND CHRNB2 FOR NICOTINE ADDICTION - DRUG PROFILE
  • Depression
  • Smoking Cessation
  • Smoking Statistics
  • Therapy
  • Suven Life Sciences Ltd

The company offers APIs in the therapeutic areas of antibiotic, oncology, cardiovascular, urology, gastrointestinal, antiviral and respiratory, among others.

  • Smoking Cessation
  • Smoking Statistics
  • United States
  • Product Initiative
  • Invion Limited

The company offers APIs in the therapeutic areas of antibiotic, oncology, cardiovascular, urology, gastrointestinal, antiviral and respiratory, among others.

  • Healthcare
  • Smoking Cessation
  • Smoking Statistics
  • United States
  • Product Initiative

Its products find application in the therapeutic areas of gastrointestinal, cardiovascular, respiratory system, central nervous system, anti-infectives, oncology, allergy and immune system, dermatology, and others.

  • Smoking Cessation
  • United States
  • Company
  • Demand
  • Orexigen Therapeutics, Inc.

It offers products for the treatment of respiratory, cardiovascular and metabolic diseases and conditions, infection, inflammation, cancer, ophthalmic diseases, neurological problems, pain, tissue repair, gastrointestinal diseases, women' s health issues, orphan diseases and genitourina

  • Smoking Cessation
  • United States
  • Company
  • Product Initiative
  • Omeros Corporation
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction

gastrointestinal disorders and irritable bowel syndrome. ##-Oct-2017 Addex Therapeutics announced that the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) has awarded a USD ##. ## million grant to support human studies of ADX## for the treatment

  • OTC
  • Smoking Cessation
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction

gastrointestinal disorders and irritable bowel syndrome. ##-Feb-2017 Addex Therapeutics announced that it has raised gross proceeds of CHF ##. ## million through a private placement in which ##. ## million treasury shares were placed at CHF## per share.

  • OTC
  • Pharmaceutical
  • Smoking Cessation
  • United States
  • Product Initiative